DexCom Inc (DXCM)

Pretax margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Earnings before tax but after interest (EBT) (ttm)	US$ in thousands	710,400	597,400	503,200	419,200	390,800	264,000	229,800	251,600	256,800	404,600	367,700	316,800	297,900	238,000	208,700	153,200	104,200	-167,000	-168,000	-129,100
Revenue (ttm)	US$ in thousands	3,603,200	3,380,700	3,175,600	3,001,700	2,889,200	2,740,300	2,599,600	2,478,000	2,333,800	2,206,500	2,058,200	1,914,400	1,823,900	1,754,600	1,659,800	1,555,100	1,426,800	1,302,000	1,187,500	1,108,600
Pretax margin		19.72%	17.67%	15.85%	13.97%	13.53%	9.63%	8.84%	10.15%	11.00%	18.34%	17.87%	16.55%	16.33%	13.56%	12.57%	9.85%	7.30%	-12.83%	-14.15%	-11.65%

December 31, 2023 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $710,400K ÷ $3,603,200K
= 19.72%

The pretax margin of Dexcom Inc has shown a consistent upward trend over the past eight quarters, indicating an improving profitability before taxes. The company's pretax margin increased from 7.34% in Q1 2022 to 19.61% in Q4 2023, reflecting a steady growth in profitability. This positive trend suggests that Dexcom Inc has been effectively managing its expenses and generating higher revenues relative to costs. The company's ability to maintain and enhance its pretax margin signifies a promising financial performance and operational efficiency during the period under review.